UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies

计划入组 40 人 · 首次发布于 2026 年 1 月 16 日

Efficacy, Safety and Pharmacokinetics of LP-003 in Peanut Allergic Patients

计划入组 80 人 · 首次发布于 2026 年 8 月 25 日

Flow CAST® Peanut Trial

计划入组 245 人 · 首次发布于 2026 年 8 月 20 日

DPX-based vaccines (food allergies/ peanut allergy)

Peanut(Palforzia 12 Mg (level 3), Palforzia 120 Mg (level 7), Palforzia 160 Mg (level 8), Palforzia 20 Mg (level 4), Palforzia 200 Mg (level 9), Palforzia 240 Mg (level 10), Palforzia 3 Mg (level 1), Palforzia 300 Mg (level 11), Palforzia 40 Mg (level 5), Palforzia 6 Mg (level 2), Palforzia 80 Mg (level 6), Palforzia Initial Dose Escalation)

Peanut oil

DBV Technologies

France

Allegis Holdings, LLC

United States

Allegis Pharmaceuticals, LLC

United States

NIH Trial Shows Home-Based Peanut Butter Therapy Successfully Treats High-Threshold Peanut Allergies

FDA Issues Class II Risk Warning for Ritz Peanut Butter Crackers Due to Mislabeling That Could Trigger Life-Threatening Allergic Reactions

Palforzia Receives Positive CHMP Opinion for Peanut Allergy Treatment in Toddlers